Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin.


Journal

Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652

Informations de publication

Date de publication:
31 Dec 2024
Historique:
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: ppublish

Résumé

Tetanus toxin (TeNT) is one of the most toxic proteins. Neutralizing antibodies against TeNT are effective in prevention and treatment. In this study, 14 anti-tetanus nanobodies were obtained from a phage display nanobody library by immunizing a camel with the C-terminal receptor-binding domain of TeNT (TeNT-Hc) as the antigen. After fusion with the human Fc fragment, 11 chimeric heavy-chain antibodies demonstrated nanomolar binding toward TeNT-Hc. The results of toxin neutralization experiments showed that T83-7, T83-8, and T83-13 completely protected mice against 20 × the median lethal dose (LD

Identifiants

pubmed: 38934499
doi: 10.1080/21645515.2024.2366641
doi:

Substances chimiques

Tetanus Toxin 0
Antibodies, Neutralizing 0
Single-Domain Antibodies 0
Immunoglobulin Heavy Chains 0
Antibodies, Bacterial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2366641

Auteurs

Kexuan Cheng (K)

Department of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Jiansheng Lu (J)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Jiazheng Guo (J)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Rong Wang (R)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Lei Chen (L)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Xi Wang (X)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Yujia Jiang (Y)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Yating Li (Y)

Department of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Changyan Xu (C)

Department of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Qinglin Kang (Q)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Gulisaina Qiaerxie (G)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Peng Du (P)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Chen Gao (C)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Yunzhou Yu (Y)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Zhixin Yang (Z)

Laboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.

Wei Wang (W)

Department of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH